These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17001259)

  • 1. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Munakata J; Benner JS; Becker S; Dezii CM; Hazard EH; Tierce JC
    Med Care; 2006 Oct; 44(10):893-9. PubMed ID: 17001259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
    Goldie SJ; Paltiel AD; Weinstein MC; Losina E; Seage GR; Kimmel AD; Walensky RP; Sax PE; Freedberg KA
    Am J Med; 2003 Dec; 115(8):632-41. PubMed ID: 14656616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men.
    Zaric GS; Bayoumi AM; Brandeau ML; Owens DK
    Med Decis Making; 2008; 28(3):359-76. PubMed ID: 18349433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
    Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
    J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
    Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
    Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of 'test and treat' policy for antiretroviral therapy among heterosexual HIV population in India.
    Singh M; Sharma A; Bahuguna P; Jyani G; Prinja S
    Indian J Med Res; 2022 Jun; 156(6):705-714. PubMed ID: 37056069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.